MCL1 and hepatocellular carcinoma: Finally, ABT-263 can increase the stability of Mcl-1 mRNA and protein as previously described in hepatocellular carcinoma cells [38], suggesting that treatment with ABT-263 alone might activate resistance mechanisms by increasing anti-apoptotic Mcl-1.